Jump Financial, LLC Bellus Health Inc. Transaction History

Jump Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 21, 2024	BUY	$7.14 - $8.53 $130,890 - $156,371	18,332 New	18,332 $131,000
Q1 2023 May 03, 2023	SELL	$7.14 - $8.53 $343,205 - $410,020	-48,068 Reduced 72.39%	18,332 $131,000
Q4 2022 Feb 13, 2023	SELL	$8.22 - $10.76 $253,998 - $332,484	-30,900 Reduced 31.76%	66,400 $545,000
Q3 2022 Nov 07, 2022	SELL	$8.95 - $12.0 $42,968 - $57,612	-4,801 Reduced 4.7%	97,300 $1.03 Million
Q2 2022 Aug 09, 2022	BUY	$6.46 - $10.02 $659,572 - $1.02 Million	102,101 New	102,101 $944,000
Q1 2022 May 12, 2022	SELL	$5.56 - $7.99 $425,301 - $611,179	-76,493 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$5.26 - $8.3 $402,353 - $634,891	76,493 New	76,493 $616,000
Q3 2021 Nov 12, 2021	SELL	$2.7 - $6.64 $177,390 - $436,248	-65,700 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.61 $130,309 - $193,159	41,900 Added 176.05%	65,700 $204,000
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $72,114 - $109,004	23,800 New	23,800 $91,000
Q4 2020 Feb 12, 2021	SELL	$2.27 - $3.3 $50,621 - $73,590	-22,300 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.14 - $12.02 $47,722 - $268,046	22,300 New	22,300 $51,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.